Why Did SoundHound AI Stock Go Up?
SoundHound AI (NASDAQ:SOUN) has moved higher in recent days, breaking…
Sell
35
PCRX Quote, Financials, Valuation and Earnings
Last price:
$20.79
Seasonality move
:
9.11%
Day range:
$20.15 - $21.12
52-week range:
$18.80 - $27.64
Dividend yield:
0%
P/E ratio:
46.56x
P/S ratio:
1.34x
P/B ratio:
1.23x
Volume:
1M
Avg. volume:
1.1M
1-year change:
-7.48%
Market cap:
$893.6M
Revenue:
$701M
EPS (TTM):
$0.45
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PCRX
Pacira Biosciences, Inc.
|
$201.9M | $0.90 | 10.43% | 608.41% | $29.71 |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$110.8M | $0.08 | 55.26% | -88.43% | $31.63 |
|
CRMD
CorMedix, Inc.
|
$126.7M | $0.80 | 195.3% | 90.44% | $15.57 |
|
FOLD
Amicus Therapeutics, Inc.
|
$179.8M | $0.16 | 20.08% | 234.42% | $14.50 |
|
HOLX
Hologic, Inc.
|
$1.1B | $1.10 | 5% | 26.98% | $76.92 |
|
KRYS
Krystal Biotech, Inc.
|
$106.8M | $1.61 | 35.17% | 42.95% | $276.60 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PCRX
Pacira Biosciences, Inc.
|
$20.77 | $29.71 | $893.6M | 46.56x | $0.00 | 0% | 1.34x |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$26.65 | $31.63 | $3.3B | -- | $0.00 | 0% | 10.71x |
|
CRMD
CorMedix, Inc.
|
$7.44 | $15.57 | $586.2M | 3.62x | $0.00 | 0% | 2.51x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.27 | $14.50 | $4.4B | -- | $0.00 | 0% | 7.30x |
|
HOLX
Hologic, Inc.
|
$75.11 | $76.92 | $16.7B | 30.25x | $0.00 | 0% | 4.16x |
|
KRYS
Krystal Biotech, Inc.
|
$289.13 | $276.60 | $8.4B | 43.37x | $0.00 | 0% | 23.12x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PCRX
Pacira Biosciences, Inc.
|
36.9% | -0.471 | 38.41% | 3.38x |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
41.85% | -0.649 | 5.02% | 3.07x |
|
CRMD
CorMedix, Inc.
|
1.16% | 2.954 | 0.48% | 1.60x |
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | -0.323 | 18.22% | 1.91x |
|
HOLX
Hologic, Inc.
|
34.23% | 1.135 | 17.49% | 2.91x |
|
KRYS
Krystal Biotech, Inc.
|
0.83% | -0.755 | 0.19% | 9.43x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PCRX
Pacira Biosciences, Inc.
|
$130.9M | $13.2M | 1.58% | 2.81% | 7.33% | $57M |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$90.5M | $8.5M | -15.75% | -29.4% | 8.59% | -$1.8M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
|
HOLX
Hologic, Inc.
|
$580.7M | $253M | 7.59% | 11.59% | 24.11% | $324.7M |
|
KRYS
Krystal Biotech, Inc.
|
$92.1M | $41.4M | 19.74% | 19.91% | 42.31% | $38M |
Pacira Biosciences, Inc. vs. Competitors
-
Which has Higher Returns PCRX or ARQT?
Arcutis Biotherapeutics, Inc. has a net margin of 3.03% compared to Pacira Biosciences, Inc.'s net margin of 7.47%. Pacira Biosciences, Inc.'s return on equity of 2.81% beat Arcutis Biotherapeutics, Inc.'s return on equity of -29.4%.
Company Gross Margin Earnings Per Share Invested Capital PCRXPacira Biosciences, Inc.72.93% $0.12 $1.2B ARQTArcutis Biotherapeutics, Inc.91.25% $0.06 $271.8M -
What do Analysts Say About PCRX or ARQT?
Pacira Biosciences, Inc. has a consensus price target of $29.71, signalling upside risk potential of 43.06%. On the other hand Arcutis Biotherapeutics, Inc. has an analysts' consensus of $31.63 which suggests that it could grow by 18.67%. Given that Pacira Biosciences, Inc. has higher upside potential than Arcutis Biotherapeutics, Inc., analysts believe Pacira Biosciences, Inc. is more attractive than Arcutis Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PCRXPacira Biosciences, Inc.3 2 0 ARQTArcutis Biotherapeutics, Inc.4 1 0 -
Is PCRX or ARQT More Risky?
Pacira Biosciences, Inc. has a beta of 0.224, which suggesting that the stock is 77.636% less volatile than S&P 500. In comparison Arcutis Biotherapeutics, Inc. has a beta of 1.710, suggesting its more volatile than the S&P 500 by 70.962%.
-
Which is a Better Dividend Stock PCRX or ARQT?
Pacira Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcutis Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacira Biosciences, Inc. pays -- of its earnings as a dividend. Arcutis Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PCRX or ARQT?
Pacira Biosciences, Inc. quarterly revenues are $179.5M, which are larger than Arcutis Biotherapeutics, Inc. quarterly revenues of $99.2M. Pacira Biosciences, Inc.'s net income of $5.4M is lower than Arcutis Biotherapeutics, Inc.'s net income of $7.4M. Notably, Pacira Biosciences, Inc.'s price-to-earnings ratio is 46.56x while Arcutis Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacira Biosciences, Inc. is 1.34x versus 10.71x for Arcutis Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PCRXPacira Biosciences, Inc.1.34x 46.56x $179.5M $5.4M ARQTArcutis Biotherapeutics, Inc.10.71x -- $99.2M $7.4M
-
Which has Higher Returns PCRX or CRMD?
CorMedix, Inc. has a net margin of 3.03% compared to Pacira Biosciences, Inc.'s net margin of 49.9%. Pacira Biosciences, Inc.'s return on equity of 2.81% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital PCRXPacira Biosciences, Inc.72.93% $0.12 $1.2B CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About PCRX or CRMD?
Pacira Biosciences, Inc. has a consensus price target of $29.71, signalling upside risk potential of 43.06%. On the other hand CorMedix, Inc. has an analysts' consensus of $15.57 which suggests that it could grow by 109.29%. Given that CorMedix, Inc. has higher upside potential than Pacira Biosciences, Inc., analysts believe CorMedix, Inc. is more attractive than Pacira Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PCRXPacira Biosciences, Inc.3 2 0 CRMDCorMedix, Inc.4 0 0 -
Is PCRX or CRMD More Risky?
Pacira Biosciences, Inc. has a beta of 0.224, which suggesting that the stock is 77.636% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.358, suggesting its more volatile than the S&P 500 by 35.753%.
-
Which is a Better Dividend Stock PCRX or CRMD?
Pacira Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacira Biosciences, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PCRX or CRMD?
Pacira Biosciences, Inc. quarterly revenues are $179.5M, which are larger than CorMedix, Inc. quarterly revenues of $104.3M. Pacira Biosciences, Inc.'s net income of $5.4M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Pacira Biosciences, Inc.'s price-to-earnings ratio is 46.56x while CorMedix, Inc.'s PE ratio is 3.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacira Biosciences, Inc. is 1.34x versus 2.51x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PCRXPacira Biosciences, Inc.1.34x 46.56x $179.5M $5.4M CRMDCorMedix, Inc.2.51x 3.62x $104.3M $108.6M
-
Which has Higher Returns PCRX or FOLD?
Amicus Therapeutics, Inc. has a net margin of 3.03% compared to Pacira Biosciences, Inc.'s net margin of 10.24%. Pacira Biosciences, Inc.'s return on equity of 2.81% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.
Company Gross Margin Earnings Per Share Invested Capital PCRXPacira Biosciences, Inc.72.93% $0.12 $1.2B FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M -
What do Analysts Say About PCRX or FOLD?
Pacira Biosciences, Inc. has a consensus price target of $29.71, signalling upside risk potential of 43.06%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 1.61%. Given that Pacira Biosciences, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Pacira Biosciences, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PCRXPacira Biosciences, Inc.3 2 0 FOLDAmicus Therapeutics, Inc.0 7 0 -
Is PCRX or FOLD More Risky?
Pacira Biosciences, Inc. has a beta of 0.224, which suggesting that the stock is 77.636% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.417, suggesting its less volatile than the S&P 500 by 58.311%.
-
Which is a Better Dividend Stock PCRX or FOLD?
Pacira Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacira Biosciences, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PCRX or FOLD?
Pacira Biosciences, Inc. quarterly revenues are $179.5M, which are larger than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Pacira Biosciences, Inc.'s net income of $5.4M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Pacira Biosciences, Inc.'s price-to-earnings ratio is 46.56x while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacira Biosciences, Inc. is 1.34x versus 7.30x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PCRXPacira Biosciences, Inc.1.34x 46.56x $179.5M $5.4M FOLDAmicus Therapeutics, Inc.7.30x -- $169.1M $17.3M
-
Which has Higher Returns PCRX or HOLX?
Hologic, Inc. has a net margin of 3.03% compared to Pacira Biosciences, Inc.'s net margin of 17.85%. Pacira Biosciences, Inc.'s return on equity of 2.81% beat Hologic, Inc.'s return on equity of 11.59%.
Company Gross Margin Earnings Per Share Invested Capital PCRXPacira Biosciences, Inc.72.93% $0.12 $1.2B HOLXHologic, Inc.55.33% $0.83 $7.7B -
What do Analysts Say About PCRX or HOLX?
Pacira Biosciences, Inc. has a consensus price target of $29.71, signalling upside risk potential of 43.06%. On the other hand Hologic, Inc. has an analysts' consensus of $76.92 which suggests that it could grow by 2.41%. Given that Pacira Biosciences, Inc. has higher upside potential than Hologic, Inc., analysts believe Pacira Biosciences, Inc. is more attractive than Hologic, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PCRXPacira Biosciences, Inc.3 2 0 HOLXHologic, Inc.1 17 0 -
Is PCRX or HOLX More Risky?
Pacira Biosciences, Inc. has a beta of 0.224, which suggesting that the stock is 77.636% less volatile than S&P 500. In comparison Hologic, Inc. has a beta of 0.695, suggesting its less volatile than the S&P 500 by 30.493%.
-
Which is a Better Dividend Stock PCRX or HOLX?
Pacira Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hologic, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacira Biosciences, Inc. pays -- of its earnings as a dividend. Hologic, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PCRX or HOLX?
Pacira Biosciences, Inc. quarterly revenues are $179.5M, which are smaller than Hologic, Inc. quarterly revenues of $1B. Pacira Biosciences, Inc.'s net income of $5.4M is lower than Hologic, Inc.'s net income of $187.3M. Notably, Pacira Biosciences, Inc.'s price-to-earnings ratio is 46.56x while Hologic, Inc.'s PE ratio is 30.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacira Biosciences, Inc. is 1.34x versus 4.16x for Hologic, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PCRXPacira Biosciences, Inc.1.34x 46.56x $179.5M $5.4M HOLXHologic, Inc.4.16x 30.25x $1B $187.3M
-
Which has Higher Returns PCRX or KRYS?
Krystal Biotech, Inc. has a net margin of 3.03% compared to Pacira Biosciences, Inc.'s net margin of 81.15%. Pacira Biosciences, Inc.'s return on equity of 2.81% beat Krystal Biotech, Inc.'s return on equity of 19.91%.
Company Gross Margin Earnings Per Share Invested Capital PCRXPacira Biosciences, Inc.72.93% $0.12 $1.2B KRYSKrystal Biotech, Inc.94.21% $2.66 $1.1B -
What do Analysts Say About PCRX or KRYS?
Pacira Biosciences, Inc. has a consensus price target of $29.71, signalling upside risk potential of 43.06%. On the other hand Krystal Biotech, Inc. has an analysts' consensus of $276.60 which suggests that it could fall by -4.33%. Given that Pacira Biosciences, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe Pacira Biosciences, Inc. is more attractive than Krystal Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PCRXPacira Biosciences, Inc.3 2 0 KRYSKrystal Biotech, Inc.11 0 0 -
Is PCRX or KRYS More Risky?
Pacira Biosciences, Inc. has a beta of 0.224, which suggesting that the stock is 77.636% less volatile than S&P 500. In comparison Krystal Biotech, Inc. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.705%.
-
Which is a Better Dividend Stock PCRX or KRYS?
Pacira Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacira Biosciences, Inc. pays -- of its earnings as a dividend. Krystal Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PCRX or KRYS?
Pacira Biosciences, Inc. quarterly revenues are $179.5M, which are larger than Krystal Biotech, Inc. quarterly revenues of $97.8M. Pacira Biosciences, Inc.'s net income of $5.4M is lower than Krystal Biotech, Inc.'s net income of $79.4M. Notably, Pacira Biosciences, Inc.'s price-to-earnings ratio is 46.56x while Krystal Biotech, Inc.'s PE ratio is 43.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacira Biosciences, Inc. is 1.34x versus 23.12x for Krystal Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PCRXPacira Biosciences, Inc.1.34x 46.56x $179.5M $5.4M KRYSKrystal Biotech, Inc.23.12x 43.37x $97.8M $79.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Goldman Sachs Going to Go Up?
Shares of financial giant Goldman Sachs (NYSE:GS) have soared by…
How High Will MSTR Stock Go?
After several months of pressure, shares of Bitcoin treasury Strategy…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
59
RGC alert for Jan 23
Regencell Bioscience Holdings Ltd. [RGC] is up 40.39% over the past day.
Buy
70
BNR alert for Jan 23
Burning Rock Biotech Ltd. [BNR] is up 33.29% over the past day.
Buy
76
HYMC alert for Jan 23
Hycroft Mining Holding Corp. [HYMC] is up 17.39% over the past day.
